International Stem Cell ISCO
OTC ISCO
$0.21 -0.05 (-19.23%)
As of: Oct 21, 2026 · 10:19 AM EDT

International Stem Cell (ISCO) EV to EBIT (2025)

Updated

International Stem Cell's (ISCO) EV to EBIT stood at 0.77 in Q3 2025.

Analysis

International Stem Cell (ISCO) EV to EBIT (2025) Analysis & Trends

On a TTM basis, International Stem Cell's EV to EBIT came in at -36.37 as of Sep 30, 2025.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 International Stem Cell 1.36 Mn -2.61 Mn 1.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 0.77
API Access

International Stem Cell EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=ISCO&period=max&api_key=YOUR_API_KEY